1. KD. Tripathi. Drugs Acting on Skin and Mucous Membranes. Essentials of medical pharmacology. Seventh edition. 2013. Page – 895-896.
2. Craig Burkhart, Dean Morrell and Lowell Goldsmith. Dermatological pharmacology. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1806 – 1807.
3. Azidus Brasil. Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients with Psoriasis (halobetasol). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on September 2010] [Accessed 10th December 2020] https://clinicaltrials.gov/ct2/show/NCT00715975
4. Therapeutics, Inc. A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects with Plaque Psoriasis. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on May 2016] [Accessed 10th December 2020] https://clinicaltrials.gov/ct2/show/NCT01610596
5. Jeffrey Bernhard, Claire Whitmore, Cynthia Guzzo, Irwin Kantor, Robert E.Kalb, Charles Ellis, Edmund H.Schwartzel and John R.GibsonMB. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: Report on two double-blind, vehicle-controlled studies. Sciencedirect.com. November 2008. [Accessed 10th December 2020] https://www.sciencedirect.com/science/article/abs/pii/0190962291703202
6. RANBAXY. U.S. Food & Drug Administration. [Revised on March 2012] [Accessed 10th December 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019968s011lbl.pdf